^
Association details:
| Biomarker: | RARA positive |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Amnolake (tamibarotene) (RARα agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML
Published date:
12/05/2020
Excerpt:
Syros presented new data from its fully enrolled Phase 2 trial evaluating the safety and efficacy of SY-1425 in combination with azacitidine....in RARA-positive relapsed or refractory (R/R) AML patients...Overall response rate (ORR) was 67% (12/18), with a composite CR rate of 61%, (11/18) including nine patients (50%) achieving a complete response (CR), two patients (11%) achieving a complete response with incomplete blood count recovery (CRi).
Secondary therapy:
azacitidine
